
    
      Phase 1/2 Multicenter study:

        -  Phase 1 portion is open-label to evaluate the safety of ARQ 197 administered in
           combination with irinotecan and cetuximab.

        -  Phase 2 portion is designed as a randomized, double-blind placebo-controlled study to
           assess the efficacy and safety of ARQ 197 or matching placebo administered in
           combination with irinotecan and cetuximab.
    
  